Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA, is a specialty pharmaceutical company focused on non-opioid pain management that entered the public markets through a SPAC business combination with Decathlon Acquisition Corp., which completed its IPO in 2021. The company operates in the healthcare and life sciences sector, with its lead program targeting musculoskeletal and spinal pain. Semnur filed a Form 10-Q with the SEC on May 16, 2025, accession number 0001213900-25-044889, reflecting its status as a reporting public company following the de-SPAC transaction. Investors and researchers seeking complete filing history, deal timelines, and sponsor data for DECA and thousands of other SPAC transactions can sign up for full access at SpacDesk.